Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and fSRT vs PULSAR for NSCLC Brain Metastases
NCT04889066Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab in brain metastases, sponsored by UT Southwestern Medical Center. Planned start Oct 2024; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT04889066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889066.